Cargando…

Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES

BACKGROUND: Osteoporosis (OP) and osteopenia are common bone disorders in old age, and lots of patients suffering from OP or osteopenia need to take antiplatelet agents to treat basic diseases. However, clinical data on the link between osteopenia or OP and antiplatelet agents are limited. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Hao, Wang, Jiuxiang, Zhu, Yujun, Hu, Zhimu, Wang, Ziwen, Qiao, Mingzhu, Jiang, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396674/
https://www.ncbi.nlm.nih.gov/pubmed/36017309
http://dx.doi.org/10.3389/fendo.2022.945159
_version_ 1784771979231887360
author Lv, Hao
Wang, Jiuxiang
Zhu, Yujun
Hu, Zhimu
Wang, Ziwen
Qiao, Mingzhu
Jiang, Ting
author_facet Lv, Hao
Wang, Jiuxiang
Zhu, Yujun
Hu, Zhimu
Wang, Ziwen
Qiao, Mingzhu
Jiang, Ting
author_sort Lv, Hao
collection PubMed
description BACKGROUND: Osteoporosis (OP) and osteopenia are common bone disorders in old age, and lots of patients suffering from OP or osteopenia need to take antiplatelet agents to treat basic diseases. However, clinical data on the link between osteopenia or OP and antiplatelet agents are limited. METHODS: Data in this study were collected and screened from the NHANES from 2013 to 2014 and 2017 to 2018. The variables were extracted from interviews and compared between OP or osteopenia participants and normal. The relationship between OP or osteopenia and taking antiplatelet drugs was analyzed by weighted multivariate logistic regression RESULTS: After excluding individuals who were not eligible and had invalid data, we finally identified 894 participants for inclusion in the study. We found a negative association between OP or osteopenia and taking antiplatelet agents (OR = 0.53; 95% CI, 0.33–0.84; p < 0.05). These results did not change on multiple imputations (OR = 0.32, 95% CI, 0.19–0.56; p <0.01). In the subgroup analyses, the associations were more significant in women (OR = 0.18, 95% CI, 0.05–0.62; p <0.05). CONCLUSION: This study demonstrated that the association between OP or osteopenia and taking antiplatelet agents was significant. Therefore, it is necessary to confirm the result by extending further research.
format Online
Article
Text
id pubmed-9396674
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93966742022-08-24 Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES Lv, Hao Wang, Jiuxiang Zhu, Yujun Hu, Zhimu Wang, Ziwen Qiao, Mingzhu Jiang, Ting Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Osteoporosis (OP) and osteopenia are common bone disorders in old age, and lots of patients suffering from OP or osteopenia need to take antiplatelet agents to treat basic diseases. However, clinical data on the link between osteopenia or OP and antiplatelet agents are limited. METHODS: Data in this study were collected and screened from the NHANES from 2013 to 2014 and 2017 to 2018. The variables were extracted from interviews and compared between OP or osteopenia participants and normal. The relationship between OP or osteopenia and taking antiplatelet drugs was analyzed by weighted multivariate logistic regression RESULTS: After excluding individuals who were not eligible and had invalid data, we finally identified 894 participants for inclusion in the study. We found a negative association between OP or osteopenia and taking antiplatelet agents (OR = 0.53; 95% CI, 0.33–0.84; p < 0.05). These results did not change on multiple imputations (OR = 0.32, 95% CI, 0.19–0.56; p <0.01). In the subgroup analyses, the associations were more significant in women (OR = 0.18, 95% CI, 0.05–0.62; p <0.05). CONCLUSION: This study demonstrated that the association between OP or osteopenia and taking antiplatelet agents was significant. Therefore, it is necessary to confirm the result by extending further research. Frontiers Media S.A. 2022-08-09 /pmc/articles/PMC9396674/ /pubmed/36017309 http://dx.doi.org/10.3389/fendo.2022.945159 Text en Copyright © 2022 Lv, Wang, Zhu, Hu, Wang, Qiao and Jiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Lv, Hao
Wang, Jiuxiang
Zhu, Yujun
Hu, Zhimu
Wang, Ziwen
Qiao, Mingzhu
Jiang, Ting
Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES
title Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES
title_full Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES
title_fullStr Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES
title_full_unstemmed Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES
title_short Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES
title_sort association between osteoporosis or osteopenia and taking antiplatelet agents in general us population of nhanes
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396674/
https://www.ncbi.nlm.nih.gov/pubmed/36017309
http://dx.doi.org/10.3389/fendo.2022.945159
work_keys_str_mv AT lvhao associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes
AT wangjiuxiang associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes
AT zhuyujun associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes
AT huzhimu associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes
AT wangziwen associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes
AT qiaomingzhu associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes
AT jiangting associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes